Compare Stocks → The system that called 2023’s top 7 stocks is at it again… (From WealthPress) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:AMPENASDAQ:ATNFNASDAQ:BDRXNASDAQ:DRMA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPEAmpio Pharmaceuticals$0.32-0.3%$1.19$0.14▼$8.30$365K1.96140,903 shs8,413 shsATNF180 Life Sciences$1.98+9.8%$2.82$1.33▼$27.93$1.68M0.44105,473 shs716 shsBDRXBiodexa Pharmaceuticals$1.10-15.4%$1.16$0.67▼$20.80$1.42M1.492.50 million shs1.23 million shsDRMADermata Therapeutics$0.32-6.0%$0.40$0.23▼$3.68$2.15M0.87676,370 shs11,808 shsBeginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPEAmpio Pharmaceuticals0.00%-35.29%-65.11%-81.97%-93.14%ATNF180 Life Sciences0.00%-1.10%-22.75%-54.78%-91.76%BDRXBiodexa Pharmaceuticals0.00%+72.87%-19.75%-31.22%-92.82%DRMADermata Therapeutics0.00%+6.73%-16.58%-28.90%-79.10%If you have $2,500 bucks… check this out (Ad)This computer whiz has been averaging 234% per year with an undefeated strategy he calls… The “Income Glitch” And he’s been making out like a bandit with a 100% success rate on over 64 trade opportunities! Click here to unlock the Income Glitch training workshop for free. MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMPEAmpio PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AATNF180 Life SciencesN/AN/AN/AN/AN/AN/AN/AN/ABDRXBiodexa Pharmaceuticals2.3355 of 5 stars3.52.00.00.03.60.01.3DRMADermata TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMPEAmpio PharmaceuticalsN/AN/AN/AN/AATNF180 Life SciencesN/AN/AN/AN/ABDRXBiodexa Pharmaceuticals3.00Buy$8.00627.27% UpsideDRMADermata TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest AMPE, DRMA, ATNF, and BDRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/8/2024BDRXBiodexa PharmaceuticalsLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.00(Data available from 4/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMPEAmpio PharmaceuticalsN/AN/AN/AN/A$4.04 per shareN/AATNF180 Life SciencesN/AN/AN/AN/A($0.24) per shareN/ABDRXBiodexa Pharmaceuticals$410K3.46N/AN/A$3.93 per share0.28DRMADermata TherapeuticsN/AN/AN/AN/A$1.62 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMPEAmpio Pharmaceuticals-$8.63M-$11.01N/A∞N/AN/A-149.00%-103.79%5/13/2024 (Estimated)ATNF180 Life Sciences-$19.93MN/A0.00∞N/AN/A-320.26%-112.07%5/20/2024 (Estimated)BDRXBiodexa Pharmaceuticals-$7.66MN/A0.00N/AN/AN/AN/AN/AN/ADRMADermata Therapeutics-$7.80M-$3.65N/A∞N/AN/A-107.95%-93.59%5/9/2024 (Estimated)Latest AMPE, DRMA, ATNF, and BDRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2024Q4 2023AMPEAmpio PharmaceuticalsN/A-$2.48-$2.48-$2.48N/AN/A3/21/2024Q4 2023DRMADermata TherapeuticsN/A-$0.21-$0.21-$0.21N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMPEAmpio PharmaceuticalsN/AN/AN/AN/AN/AATNF180 Life SciencesN/AN/AN/AN/AN/ABDRXBiodexa PharmaceuticalsN/AN/AN/AN/AN/ADRMADermata TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMPEAmpio PharmaceuticalsN/A2.412.41ATNF180 Life SciencesN/A0.720.72BDRXBiodexa Pharmaceuticals0.061.261.26DRMADermata TherapeuticsN/A4.914.91OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMPEAmpio Pharmaceuticals5.73%ATNF180 Life Sciences4.07%BDRXBiodexa Pharmaceuticals17.51%DRMADermata Therapeutics8.67%Insider OwnershipCompanyInsider OwnershipAMPEAmpio Pharmaceuticals3.30%ATNF180 Life Sciences4.10%BDRXBiodexa Pharmaceuticals0.34%DRMADermata Therapeutics4.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAMPEAmpio Pharmaceuticals61.14 million1.10 millionNo DataATNF180 Life Sciences4850,000818,000No DataBDRXBiodexa Pharmaceuticals271.29 million1.28 millionNot OptionableDRMADermata Therapeutics86.66 million6.38 millionNot OptionableAMPE, DRMA, ATNF, and BDRX HeadlinesSourceHeadlineDermata to Present at the Emerging Growth Conference on April 3, 2024accesswire.com - March 27 at 4:05 PMDermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Resultsaccesswire.com - March 21 at 4:05 PMDermata Therapeutics, Inc. (DRMAW)ca.finance.yahoo.com - February 11 at 3:44 PMPresenting on the Emerging Growth Conference 67 Day 1 on February 7 Register Nowfinance.yahoo.com - February 6 at 7:49 AMDermata Therapeutics Inc DRMAmorningstar.com - February 4 at 12:48 PMDermata to Present at the Emerging Growth Conference on February 7, 2024finance.yahoo.com - February 1 at 10:31 AMDermata stock soars on patent issuance, partnership talksmsn.com - January 7 at 2:38 AMDow Turns Lower; ISM Services PMI Falls In Decembermsn.com - January 5 at 5:22 PMWhy Is Aesthetic Skin Conditions-Focused Dermata Therapeutics Stock Trading Higher Today?msn.com - January 5 at 12:22 PMWhy Is Dermata Therapeutics (DRMA) Stock Up 62% Today?investorplace.com - January 5 at 9:12 AMStocks to Watch: Dermata Therapeutics, Applied Therapeutics, Fusion Pharmaceuticalsmarketwatch.com - January 4 at 9:20 PMDermata Therapeutics Shares Surge 120% on Patent Issued in Japanmarketwatch.com - January 4 at 9:20 PMWhy Dermata Therapeutics Stock Took Off After-Hoursmsn.com - January 4 at 9:20 PMDermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosisfinance.yahoo.com - January 4 at 4:20 PMDermata Therapeutics: Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acnefinanznachrichten.de - December 21 at 1:59 PMDermata Therapeutics Stock (NASDAQ:DRMA) Dividends: History, Yield and Datesbenzinga.com - December 20 at 8:31 PMDermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acnefinance.yahoo.com - December 20 at 8:31 PMDermata Therapeutics Inc.thestreet.com - December 13 at 2:42 AMDermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rulesfinance.yahoo.com - November 16 at 1:39 PMDermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocolsfinance.yahoo.com - November 16 at 8:39 AMDermata Therapeutics GAAP EPS of -$0.54msn.com - November 10 at 10:22 AMDermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Resultsfinance.yahoo.com - November 9 at 5:47 PMDermata Therapeutics Completes Start-Up Activities to Support DMT310 Phase 3 STAR-1 Acne Trialfinance.yahoo.com - October 26 at 1:47 PMDermata to Present at the H.C. Wainwright 25th Annual Global Investment Conferencefinance.yahoo.com - August 31 at 5:27 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAmpio PharmaceuticalsNYSE:AMPEAmpio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.180 Life SciencesNASDAQ:ATNF180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.Biodexa PharmaceuticalsNASDAQ:BDRXBiodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom. The company is developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. In addition, the company offers licensing for MTD 201 (Q-octreotide) and MTD211 (Q-brexpiprazole). The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.Dermata TherapeuticsNASDAQ:DRMADermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.